Amgen Inc.

Bend Research, Inc.

Dow Global Technolgoies LLC

William Brett Caldwell

Dwayne Thomas Friesen

Dory King

Kazden Ingram

Christi Hostetler

Nathan Bennette

Kyle Kyburz

Alison Viles

Ravi Mysore Shanker

Walter Christian Babcock

Daniel Tod Smithey

Marshall David Crew

Warren Kenyon Miller

David Keith Lyon

Daniel Elmont Dobry

David Thomas Vodak

Provided herein are oral dosage forms comprising a) a core tablet comprising (i) a drug layer comprising apremilast and hypromellose acetate succinate (HPMCAS) in an amorphous solid dispersion; and (ii) a swellable layer comprising one or more swellable polymers; and b) a coating layer disposed on the core tablet, wherein the oral dosage form surface comprises at least one drug release orifice. The disclosed oral dosage forms provide once-a-day dosing of apremilast and are suitable for treating diseases or disorders ameliorated by inhibiting phosphodiesterase subtype IV (PDE4).

Formulations of apremilast

Provided are certain pharmaceutical formulations of omecamtiv mecarbil and methods for their preparation and use.

Heterocyclic compounds and their uses

Disclosed are polymers of hydroxypropyl methyl cellulose acetate succinate (HPMCAS) with unique degrees of substitution of hydroxypropoxy, methoxy, acetyl, and succinoyl groups. When used in making compositions comprising a low-solubility active agent and such polymers, the polymers provide increased aqueous concentrations and/or improved physical stability of the active agent.

Hydroxypropyl methyl cellulose acetate succinate with enhanced acetate and succinate substitution

A solid composition of a low-solubility drug and a concentration-enhancing polymer has a portion of the drug in a semi-ordered state.

Pharmaceutical compositions of semi-ordered drugs and polymers

Growing community of inventors

Bend, OR, United States of America

William Brett Caldwell